GlassScriptPhysician profile
David E Miller
NPI 1013916972
$6,418.67
in general payments reported to CMS, 2019-2025
23 companies · $1,073 in 2025
The $1,073 reported for 2025 was more than what 82% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,551 · 2020: $585 · 2021: $538 · 2022: $771 · 2023: $921 · 2024: $979 · 2025: $1,073.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,972 · Education: $1.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,971.99 |
| Education | $1.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,334.12 | 2021-2025 | |
| Allergan, INC. | $705.81 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $594.60 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $505.96 | 2022-2025 | Caplyta |
| Bausch Health US, LLC | $502.72 | 2019-2025 | Aplenzin, Wellbutrin |
| Otsuka America Pharmaceutical, INC. | $487.72 | 2019-2025 | Rexulti, Abilify Maintena |
| Alkermes, INC. | $469.63 | 2022-2025 | Lybalvi, Aristada |
| Corium, LLC | $285.26 | 2022-2024 | Azstarys |
| Janssen Pharmaceuticals, INC | $230.98 | 2019-2025 | Spravato |
| Teva Pharmaceuticals USA, INC. | $222.11 | 2019-2025 | Uzedy |
| Takeda Pharmaceuticals U.S.A., INC. | $194.65 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $175.54 | 2025 | Cobenfy |
| Lundbeck LLC | $128.18 | 2019-2021 | |
| Eisai INC. | $102.48 | 2020-2022 | |
| Vanda Pharmaceuticals INC. | $99.58 | 2019-2024 | Fanapt |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $89.74 | 2019 | |
| Axsome Therapeutics, INC. | $88.46 | 2023-2025 | Auvelity |
| Adlon Therapeutics L.P. | $63.08 | 2020 | |
| Noven Therapeutics, LLC | $43.65 | 2024 | Xelstrym |
| Neurocrine Biosciences, INC. | $39.04 | 2019-2025 | |
| Collegium Pharmaceutical, INC. | $21.75 | 2025 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $21.29 | 2024 | Quviviq |
| Shire North American Group INC | $12.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.